Patent intelligence · US
US 8859506
Glycopeptide phosphonate derivatives
Glycopeptide phosphonate derivatives
Patent details — US 8859506
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 14, 2014
- Expiration
- Oct 9, 2034
- Applicant
- THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
- Claims
- 2
- CPC classes
- A61K, A61K38/14, A61K47/06, A61K47/12
Quick answer
US 8859506 (Glycopeptide phosphonate derivatives) is held by THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC. Status: granted. Granted Oct 14, 2014. Expires Oct 9, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K38/14, A61K47/06, A61K47/12, A61K47/26, A61K47/40
More from THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12384761
Imidazolo indazole compounds as JAK inhibitors
granted -
US 12358931
3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor
granted -
US 12351561
Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
granted -
US 12285417
Methods for treating chronic obstructive pulmonary disease
granted -
US 12258316
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 12239638
Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
granted -
US 12172994
Pyrimidine compound as JAK kinase inhibitor
granted -
US 12122773
Crystalline hydrate of a JAK inhibitor compound
granted
Frequently asked questions
What is US patent 8859506?
US 8859506 (Glycopeptide phosphonate derivatives) is held by THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC. Status: granted. Granted Oct 14, 2014. Expires Oct 9, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8859506?
THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 635 pharmaceutical patents for this assignee.
When does US 8859506 expire?
Our index shows an expiration date of Oct 9, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.